Safety and Efficacy Study of RXIM002 in Severe, Relapsed or Refractory Autoimmune Diseases
Safety and Efficacy Study of RXIM002 in Severe, Relapsed or Refractory Autoimmune Diseases
Recruiting · NCT07322718 · Registry updated 2026-01-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Efficacy Study of RXIM002 in Severe, Relapsed or Refractory Autoimmune Diseases | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, autoimmune disease, immune system disorder | Recruiting | Early phase 1 | 2026-01-23 | NCT07322718 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| RiboX Therapeutics Ltd. | 4 |
| Ruijin Hospital | 454 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Ruijin Hospital | Shanghai | China | 1 |